Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy.
10.1097/CM9.0000000000001876
- Author:
Wenyan WANG
1
;
Xin WANG
2
;
Jiaqi LIU
2
;
Qiang ZHU
1
;
Xiang WANG
2
;
Pilin WANG
1
Author Information
1. Department of Breast Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
2. Department of Breast Surgical Oncology, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, Beijing 100021, China.
- Publication Type:Multicenter Study
- MeSH:
Breast Neoplasms/drug therapy*;
Female;
Humans;
Lymph Nodes;
Lymphatic Metastasis;
Neoadjuvant Therapy;
Nomograms;
Prospective Studies;
Retrospective Studies
- From:
Chinese Medical Journal
2021;135(3):333-340
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Pathological complete response (pCR) of axillary lymph nodes (ALNs) is frequently achieved in patients with clinically node-positive breast cancer after neoadjuvant chemotherapy (NAC), and ALN status is an important prognostic factor for breast cancer patients. This study aims to develop a new predictive clinical model to assess the ALN pCR rate after NAC.
METHODS:This was a retrospective series of 467 patients who had biopsy-proven positive ALNs at diagnosis and underwent ALN dissection from 2007 to 2014 at the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences. We analyzed the clinicopathologic features of the patients and developed a nomogram to predict the probability of ALN pCR. A multivariable logistic regression stepwise model was used to construct a nomogram to predict ALN pCR in node-positive patients. The adjusted area under the receiver operating characteristic curve (AUC) was calculated to quantify the ability to rank patients by risk. Internal validation was performed using the 50/50 hold-out validation method. The nomogram was externally validated with prospective cohorts of 167 patients from 2016 to 2018 at the Cancer Hospital of the Chinese Academy of Medical Sciences and 114 patients from 2018 to 2020 at Beijing Tiantan Hospital.
RESULTS:In this retrospective study, 115 (24.6%) patients achieved ALN pCR after NAC. Multivariate analysis showed that clinical tumor stage (Odds ratio [OR]: 0.321, 95% confidence interval [CI]: 0.121-0.856; P = 0.023); primary tumor response (OR: 0.189; 95% CI: 0.123-0.292; P < 0.001), and estrogen receptor status (OR: 0.530, 95% CI: 0.304-0.925; P = 0.025) were independent predictors of ALN pCR. The nomogram was constructed based on the result of multivariate analysis. In the internal validation of performance of nomogram, the AUCs for the training and test sets were 0.719 and 0.753, respectively. The nomogram was validated in external cohorts with AUCs of 0.720, which demonstrated good discriminatory power in these data sets.
CONCLUSION:We developed a nomogram to predict the likelihood of axillary pCR in node-positive breast cancer patients after NAC. The predictive model performed well in multicenter prospective external validation. This practical tool could provide information to surgeons regarding whether to perform additional ALN dissection after NAC.
TRIAL REGISTRATION:ChiCTR.org.cn, ChiCTR1800014968.
